Molecular Obesity, Potency and other Addictions in Medicinal Chemistry
Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design.

February 02, 2012 /24-7PressRelease/ -- SMi's Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design.

Leading speakers include:

Hit to lead with X-ray crystallography
o Leveraging hits with crystal structure insight
o Molecular design in team discovery
o Synchrotron beamline upgrades for pharma
Kenton Longenecker, Protein Crystallographer,

Structural Biology Department, Abbott.
Delivering impact from HTS - drawing on experiences from the Pfizer portfolio
This talk will provide specific examples in hit identification from HTS across the Pfizer portfolio, with a specific focus on:-
o Evolving approaches to compound file & subset screening
o Combining fragment screening & biophysics with small molecule HTS
o Use of chemogenomic libraries & pre-competitive screening collaborations to identify novel probes & targets
John Mathias, Head of Medicinal Chemistry -
Inflammation & Remodelling, Pfizer

Molecular obesity, potency and other addictions in medicinal chemistry
o Review of the developability issues associated with compounds of high lipophilicity
o Scientific and organisational reasons why we always tend towards such compounds
o Resisting the urge to use such compounds
Mike Hann, Director of Structural Biology Europe, GlaxoSmithKline


Key note speakers include:
o Suvit Thaisrivongs, Vice President, Discovery Chemistry, Pfizer
o Mike Hann, Director of Structural Biology Europe, GSK
o Herbert Nar, Director Structural Research, Boehringer Ingelheim
o John Mathias, Head of the Pfizer HTS CoE, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
o Jos? Duca, Head of CADD, Novartis Institutes for BioMedical Research, Inc.
o Gregor Macdonald, Head of Neuroscience Chemistry, Janssen Pharmaceuticals, Johnson & Johnson PRD

Click here to visit our website

Alternatively contact Fateja Begum on +44 (0) 20 7827 6184 or e-mail: fbegum@smi-online.co.uk

Press Release Contact Information:

EIN News